-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Estrella Immunopharma, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q1 2021 to Q3 2024.
- Estrella Immunopharma, Inc. Earnings Per Share, Diluted for the quarter ending September 30, 2024 was -0.09 USD/shares, a 94.9% increase year-over-year.
- Estrella Immunopharma, Inc. Earnings Per Share, Diluted for the twelve months ending September 30, 2024 was 1.42 USD/shares.
- Estrella Immunopharma, Inc. annual Earnings Per Share, Diluted for 2024 was -0.27 USD/shares, a 99.3% increase from 2023.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)